Table 1.

Current recommendations from guidelines

Society	Recommendation	Class of evidence
ESC (2021)	Vericiguat may be considered in worsening HFrEF patients (NYHA class II–IV) despite the administration of an ACEi (or ARNI), a β-blocker, or an MRA with the aim of reducing mortality or HF hospitalization	IIB
AHA/ACC/HFSA (2022)	Vericiguat may be considered to reduce hospitalizations and cardiovascular death in high-risk patients with HFrEF and recent worsening HF who are already receiving OMT	IIB

ACC American College of Cardiology, ACEi angiotensin converting enzyme inhibitor, AHA American Heart Association, ARNI angiotensin receptor/neprilysin inhibitor, ESC European Society of Cardiology, HF heart failure, HFrEF heart failure with reduced ejection fraction, HFSA Heart Failure Society of America, NYHA New York Heart Association, OMT optimal medical therapy, MRA mineralocorticoid receptor antagonist